Advertisement

Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission

  • Yoshikazu Iizuka
  • Masumi Aiso
  • Toshiteru Ohshima
  • Shigemasa Sawada
  • Takashi Horie
Article
  • 14 Downloads

Abstract

We have measured the serum levels of soluble CD4, CD8 and IL-2R in 43 patients with AML in complete remission (AML-CR). The sCD8 levels of AML-CR patients (443.9 ± 224.4 u/ml) were significantly high as compared to that of the normal controls (177.1 ± 76.3 u/ml),p < 0.01. The sIL-2R levels of AML-CR patients were 715.0 ± 646.3 u/ml, which significantly differed when compared to 322.1 ± 65.7 u/ml for the normal controls,p < 0.01. However, the sCD4 levels of AML-CR patients were 9.6 ± 4.7 u/ml, which did not differ from the 8.3 ± 2.6 u/ml of the normal controls. The AML-CR patients showed significantly increased sCD8 and sIL-2R levels at all ranges during the remission from one to 188 months.

The sCD8 levels and sIL-2R levels of the AML-CR patients showed a close correlation,p < 0.01. Further, the sCD8 levels and lymphokine activated killer cell cytotoxic activity showed a close correlation,p < 0.05. The presence of the activation of anti-tumor immunity may be related to the continuance of the remission in the AML-CR patients.

Key Words

sCD4 sCD8 SIL-2R AML-CR 

Abbreviations

IM

infectious mononucleosis

AILD

angio-immunoblastic lymphadenopathy

HD

Hodgkin’s disease

HL

hairy cell leukemia

AML

acute myeloid leukemia

ALL

acute lymphocytic leukemia

AML

patients

AML

pretreated patients

AML-CR

patients with AML in complete remission

PMC

peripheral mononuclear cells

NHL

non-Hodgkin’s lymphoma

ATL

adult T cell leukemia

NK-A

natural killer cell cytotoxic activity

LAK-A

lymphokine activated killer cell cytotoxic activity

References

  1. 1.
    Fujirnoto J, Levy S, Levy R: Spontaneous release of the Leu-2 (T8) molecule from human T cells.J Exp Med 159, 752 (1983).CrossRefGoogle Scholar
  2. 2.
    Fujimoto J, Stewart S J, Levy R: Immunochemical analysis of the released Leu-2 (T8) molecule.J Exp Med 160, 116 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    Rubin L A, Kurman C C, Fritz M E, Biddison W E, Boutin B, Yarchoan R, Nelson D L: Soluble interleukin 2 receptors are released from activated human cells in vivo.J Immunol 135, 3172 (1985).PubMedGoogle Scholar
  4. 4.
    Stein G, Alasevic J, Vinate F, Zanotti R, Chilosi M, Feller A C, Diamantstein T: Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanism.Bri J Haematol 75, 485 (1990).CrossRefGoogle Scholar
  5. 5.
    Tomkinson B E, Brown M C, Stephen H I P, Carrabis S. Sullivan J L: Soluble CD8 during T cell activation.J Immunol 142,2230 (1989).PubMedGoogle Scholar
  6. 6.
    Hsieh K H: Decreased production of CD8 (T8) antigen after immunotherapy.J Clin Immunol 9, 111 (1989).PubMedCrossRefGoogle Scholar
  7. 7.
    Reddy M M, Lange M, Grieco M: Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected population.J Clin Microbiol 27, 257 (1989).PubMedGoogle Scholar
  8. 8.
    Pui C H, Ip S H, Thompson E, Dodge R, Brown M, Wilimas J, Carrabis S, Kung P, Berard C W, Crist W M: Increased serum CD8 antigen level in childhood Hodgkin’s disease related to advanced stage and poor treatment outcome.Blood 73, 209 (1989).PubMedGoogle Scholar
  9. 9.
    Ho A D, Grossmann M, Knauf W, Martin H, Trumper L, Zwingers T, Sonnen R, Pralle H, Hunstein W: Plasma levels of CD8 antigen and interleukin-2 receptor antigen in patients with hairy ceil leukemia, relationship with splenectomy and with clinical response to therapy.Leukemia 3, 718 (1989).PubMedGoogle Scholar
  10. 10.
    Ho A D, Grossmann M, Trumper L, Pezzuto A, Pralle H, Boedewadt-Radzum S, Papendick U, God B, Zwingers T, Hunstein W: Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemia.Blood 75, 1119 (1990).PubMedGoogle Scholar
  11. 11.
    Pui C H, Schell M, Vodian M A, Kline S, Mirro J, Crist W M, Behm F: Serum CD4, CD8, and interleukin-2 receptor levels in childhood acute myeloid leukemia.Leukemia 5, 249 (1991).PubMedGoogle Scholar
  12. 12.
    Pui C H, Ip S H, Iflah S, Behm F G, Grose B H, Dodge R K, Crist W M, Furman W L, Murphy S B, Rivera G K: Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia.Blood 71, 1135 (1988).PubMedGoogle Scholar
  13. 13.
    Pui C H, Ip S H, Kung P, Dodge R K, Berard C W, Cnst W M, Murphy S B: High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin’s lymphoma.Blood 70, 624 (1987).PubMedGoogle Scholar
  14. 14.
    Steis R G, Marcon L, Clark J, Urba W, Longo D L, Neison D L, Maluish A E: Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia.Blood 77, 1304 (1988).Google Scholar
  15. 15.
    Motoi T, Uchiyama T, Uchino H, Ueda R, Araki K: Serum soluble interleukin-2 receptor levels in patients with adult T cell leukemia and human T-cell leukemia/lymphoma virus Type-I seropositive healthy carriers.Jpn J Cancer Res 79, 593 (1988).PubMedGoogle Scholar
  16. 16.
    Southern J T, Fallon J T, Dec G W, Jacobs D M, Cosimi A B, Brown M C, Kung P C, Colvin R B: A comparison of serum interleukin 2 receptor levels and endomyocardial biopsy grades in the monitoring of cardiac allograft rejection (abstract).J Heart Transpl 5, 370 (1986).Google Scholar
  17. 17.
    Dupere S, Obiri N, Lackey A, Emma D, Yannelli J, Orr D, Birch R, O’Connor T E: Patterns of cytokines related by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vivo.J Biol Resp Modi 9, 140 (1990).Google Scholar
  18. 18.
    Ohshima T, Takeuchi J: Short term intensive chemotherapy regimens for adult acute myeloid leukemia-DCMP-85 vs DBMP-85, in Kimura K, Yamada K, Frei E III, Catter S K (eds):Cancer Chemotherapy: Challenges for the future, p. 153. Excepta Medica, Japan (1988).Google Scholar
  19. 19.
    Takeuchi J, Endo M, Kanemaru M, Murakami J, Matsui K, Iizuka Y, Horikoshi A, Kitami I, Ohshima T: Short term intensive chemotherapy without maintenance for adult acute myeloid leukemia (AML) (abstract).Blood 76 (suppl 1), 325a (1990).Google Scholar
  20. 20.
    Bennet J M, Catovsky D, Daniel M T, Flandrin G, Galton D A G, Grainick G R, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia.Ann Intern Med 103, 620 (1985).Google Scholar
  21. 21.
    Iizuka Y, Sakurai T, Horikoshi A, Ohshima T: Inhibitory activity of interleukin 2-activated lymphocytes on human granulocyte precursors (CFU-g).Int J Cell Cloning 6, 146 (1988).PubMedCrossRefGoogle Scholar
  22. 22.
    Dalgleish A G: The T4 molecule: function and structure.Immunol Today 7, 142 (1986).CrossRefGoogle Scholar
  23. 23.
    Liu M A, Liu T: Effect of recombinant soluble CD4 on human peripheral blood lymphocyte responses in vitro.J Clin Invest 82, 2176 (1988).PubMedCrossRefGoogle Scholar
  24. 24.
    Meuer S C, Schlossman S F, Reinherz E L: Clonal analysis of human cytotoxic T lymphocytes.Proc Natl Acad Sci USA 79, 4395 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1992

Authors and Affiliations

  • Yoshikazu Iizuka
    • 1
  • Masumi Aiso
    • 1
  • Toshiteru Ohshima
    • 1
  • Shigemasa Sawada
    • 1
  • Takashi Horie
    • 1
  1. 1.First Department of Internal MedicineNihon University, School of MedicineTokyoJapan

Personalised recommendations